Ophthotech Corporation to Present at 31st Annual J.P. Morgan Healthcare Conference
1/3/2013 6:21:31 AM
More...
|
Positive Results From Phase 2b Study of Ophthotech Corporation's Novel Anti-PDGF Combination Agent Fovista™ to be Presented at American Academy of Ophthalmology Retina Subspecialty Day
10/24/2012 9:07:30 AM
More...
|
Ophthotech Corporation Drug May Shake Up Eye Treatment Market
6/13/2012 10:16:15 AM
More...
|
Ophthotech Corporation to Present at 30th Annual J.P. Morgan Healthcare Conference
1/3/2012 8:46:19 AM
More...
|
Ophthotech Corporation Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
4/26/2010 9:12:11 AM
More...
|
Ophthotech Corporation Raises $30 Million in Series B Financing
12/15/2009 6:42:21 AM
More...
|
Ophthotech Corporation Announces Positive Results for Ophthotech's Novel Therapy for Wet AMD
5/4/2009 8:27:01 AM
More...
|
Ophthotech Treats First Patient in a Phase I Trial of Monoclonal Antibody, Volociximab, for Age-Related Macular Degeneration
11/10/2008 11:36:49 AM
More...
|
Ophthotech Enrolls First Patient in a Phase I Complement (Anti-C5) Inhibitor Trial for Macular Degeneration
10/27/2008 9:57:34 AM
More...
|
Archemix Corporation Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Ophthotech
2/19/2008 8:49:53 AM
More...
|
|